Covalon Technologies Ltd. (CVALF)
| Market Cap | 46.39M -5.0% |
| Revenue (ttm) | 23.41M -3.4% |
| Net Income | 1.18M -55.6% |
| EPS | 0.04 -64.7% |
| Shares Out | n/a |
| PE Ratio | 39.45 |
| Forward PE | 20.98 |
| Dividend | 0.11 (6.61%) |
| Ex-Dividend Date | Nov 4, 2025 |
| Volume | 100 |
| Open | 1.670 |
| Previous Close | 1.650 |
| Day's Range | 1.670 - 1.670 |
| 52-Week Range | 1.160 - 2.140 |
| Beta | 0.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About Covalon Technologies
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company’s platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secon... [Read more]
Financial Performance
In fiscal year 2025, Covalon Technologies's revenue was 32.82 million, an increase of 5.29% compared to the previous year's 31.17 million. Earnings were 2.06 million, a decrease of -22.91%.
Financial numbers in CAD Financial StatementsNews
Covalon Announces Appointment of New Director and DSU Grants
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the appointment of Dr...
Covalon Technologies Earnings Call Transcript: Q2 2026
Q2 delivered strong revenue and margin growth, with adjusted EBITDA more than doubling year-over-year. Adoption of contamination prevention products is accelerating at leading hospitals, and management expects a robust second half with continued operating leverage.
Covalon Technologies Slides: Q2 2026
Covalon Technologies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 21, 2026.
Covalon Technologies Registration statement: Q2 2026
Covalon Technologies filed a registration statement on May 21, 2026, providing details about a securities offering with the SEC.
Covalon Technologies Registration statement: Q2 2026
Covalon Technologies filed a registration statement on May 21, 2026, providing details about a securities offering with the SEC.
Covalon Technologies Earnings release: Q2 2026
Covalon Technologies released its Q2 2026 earnings on May 21, 2026, summarizing the period's financial results.
Covalon Reports 2026 Second Quarter Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 secon...
Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 resul...
Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (TSX: COV; OTCQX: CVALF), an advanced medical technologies company, today announced a series of important milestones reflecting the Com...
Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its upcoming presence at the Infusion Nurses Socie...
Covalon Announces Grant of Deferred Share Units
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the Company has gr...
Covalon Announces Voting Results from Fiscal 2025 Annual General and Special Meeting of Shareholders
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the ma...
Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 25, 2026
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the annual meeting...
Covalon Technologies Earnings Call Transcript: Q1 2026
Q1 revenue declined year-over-year, but gross margins remained strong and Q2 is already outperforming Q1. Major new hospital wins, strong customer retention, and investments in automation and IT are driving optimism for robust growth in fiscal 2026.
Covalon Technologies Earnings release: Q1 2026
Covalon Technologies released its Q1 2026 earnings on February 25, 2026, summarizing the period's financial results.
Covalon Technologies Slides: Q1 2026
Covalon Technologies has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 25, 2026.
Covalon Reports on 2026 First Quarter Results and Recent Achievements and Highlights
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 first...
Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company focused on improving patient safety an...
Covalon Announces Conference Call to Discuss First Quarter Fiscal 2026 Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q1 Fiscal 2026 resul...
Covalon Technologies Earnings Call Transcript: Q4 2025
Achieved record Q4 revenue and 5% annual growth, driven by strong U.S. and international sales, despite a decline in advanced wound care due to inventory and partner issues. Maintained high gross margins, paid a special dividend, and ended the year with strong cash and no debt.
Covalon Technologies Slides: Q4 2025
Covalon Technologies has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on December 11, 2025.
Covalon Technologies Earnings release: Q4 2025
Covalon Technologies released its Q4 2025 earnings on December 11, 2025, summarizing the period's financial results.
Covalon Reports Highest Revenue Quarter of Fiscal Year 2025, Delivers Third Consecutive Year of Revenue Growth
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2025 fourt...
Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2025 Financial Results
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q4 and year end Fisc...
Covalon Technologies Ltd. Announces Payment of First Ever Dividend, Marking a Milestone in Financial Strength
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the payment on Novemb...